GUTS:NASDAQFractyl Health, Inc. Analysis

Fractyl Health (GUTS) is trading at $0.82, comfortably above its 20‑day (0.73) and 50‑day (0.58) SMAs but still below the 200‑day average (1.12), signaling a short‑term bullish bias despite a neutral longer‑term trend. The RSI sits at 60, the MACD line is bullish (0.078 > signal 0.072) and volume is increasing, suggesting momentum may be building. However, the stock carries a high 30‑day volatility of ~106% and a beta of 2.0, underscoring pronounced price swings relative to the market. Valuation metrics are mixed: a price‑to‑book of 13× and a negative forward PE highlight current overvaluation on a balance‑sheet basis, yet analysts project a median target of $6.20, implying a potential upside of over 540% from today’s price. Recent material news adds a catalyst layer – the company reported a Q1 profit turnaround with net income of $9.22 million and EPS of $0.06, and it remains on track to release pivotal Revita data in Q4 2026 while advancing its GLP‑1 gene‑therapy trial. These clinical milestones, combined with a strong “strong‑buy” consensus from five analysts, could drive the stock higher if data prove positive, but the company’s zero revenue, negative EBITDA, and high debt‑to‑equity (284×) keep the risk profile elevated.